Trabectedin in the treatment of soft tissue sarcomas. First russian experience

Cover Page

Cite item

Full Text

Abstract

Aim of the study was to evaluate efficacy and safety of 24-hour 3 weekly CI infusion of trabectedine in patients with specific soft tissue sarcomas subtypes as a second or more treatment option. Materials and methods. 21 patients with PD after one or more lines of chemotherapy were enrolled. 12 pts. with leiomyo, 7 -synovial and 3 myxoid liposarcoma. Detailed toxicity profile evaluation was performed and the obtained data almost equals STS 201 trial. Patients received 2-9 cycles with median 4 cycles. Results. 20 patients were available for the response assessment: CR - 0, PR - 3 (15%), SD - 11 (55%), PD - 6 (30%) with the control rate (CR+PR+SD) of 70%. Conclusion. Trabectedine is effective second or more line treatment option for advanced specific STS subtypes with acceptable toxicity profile.

About the authors

A. A. Fedenko

N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences

Author for correspondence.
Email: fedenko@eesg.ru
Russian Federation

V. A. Gorbunova

N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences

Russian Federation

B. Yu. Bokhyan

N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences

Russian Federation

M. D. Aliev

N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences

Russian Federation

I. A. Istomin

N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences

Russian Federation

References

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2011 Fedenko A.A., Gorbunova V.A., Bokhyan B.Y., Aliev M.D., Istomin I.A.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС77-66671 от  09.11.2009.